

Contents lists available at ScienceDirect

Neurochemistry International

journal homepage: www.elsevier.com/locate/neuint



Human umbilical cord blood cells transfected with VEGF and L₁CAM do not differentiate into neurons but transform into vascular endothelial cells and secrete neuro-trophic factors to support neuro-genesis—a novel approach in stem cell therapy

Albert A. Rizvanov ^{a,b,c}, Andrey P. Kiyasov ^{a,d}, Ilnaz M. Gaziziov ^{a,d}, Tatyana S. Yilmaz ^{a,d}, Maxim S. Kaligin ^a, Dina I. Andreeva ^a, Aigul K. Shafigullina ^a, Darya S. Guseva ^a, Sergey L. Kiselev ^e, Keyvan Matin ^f, András Palotás ^{g,*}, Rustem R. Islamov ^{a,c}

ARTICLE INFO

Article history: Received 17 September 2008 Accepted 19 September 2008 Available online 26 September 2008

Keywords: Amyotrophic lateral sclerosis Human umbilical cord blood L₁CAM Stem cell VEGF

ABSTRACT

Genetically modified mono-nuclear cell fraction from human umbilical cord blood (HUCB) expressing human vascular endothelial growth factor (VEGF) and mouse neural L₁ cell adhesion molecule (L₁CAM) were used for gene-stem cell therapy of transgenic ^G93^A mice adopted as an animal amyotrophic lateral sclerosis (ALS) model. We generated non-viral plasmid constructs, expressing human VEGF₁₆₅ (pcDNA-VEGF) and mouse neural L₁ cell adhesion molecule (pcDNA-mL₁CAM). Mono-nuclear fraction of HUCB cells were transiently transfected by electro-poration with a mixture of expression plasmids (pcDNA-VEGF + pcDNA-mL₁CAM). Sixteen transgenic female and male mice were randomly assigned to three groups: (1) transplantation of genetically modified HUCB cells expressing L_1 and VEGF (n = 6), (2) transplantation of un-transfected HUCB cells (n = 5), and (3) control group (n = 5). In first two experimental groups 1×10^6 cells were injected retro-orbitally in pre-symptomatic 22–25-week-old $^{
m G}93^{
m A}$ mice. Our results demonstrate that HUCB cells successfully grafted into nervous tissue of ALS mice and survived for over 3 months. Therefore, genetically modified HUCB cells migrate in the spinal cord parenchyma, proliferate, but instead of transforming into nerve cells, they differentiate into endothelial cells forming new blood vessels. We propose that: (A) expression of mouse neural L₁CAM is responsible for increased homing and subsequent proliferation of transplanted cells at the site of neuro-degeneration, (B) expression of human VEGF directs HUCB cell differentiation into endothelial cells, and (C) neuroprotective effect may stem from the delivery of various neuro-trophic factors from newly formed blood

© 2008 Elsevier Ltd. All rights reserved.

1. Introduction

Neuro-trauma, stroke, and neuro-degenerative diseases are accompanied by loss of nerve cells, axon degeneration, and disrupted communication in neural networks. Developing new therapies for treating neuro-degenerative diseases is an important

challenge (Okano et al., 2007). Current treatments options are inadequate and do not provide sufficient quality of life. One of the promising cell therapy approaches to prevent secondary degeneration and support neuronal growth is neuro-transplantation of embryonic stem cells pre-differentiated into neural progenitor cells, and neural stem cells which are proposed as a source of new glial and neural cells, and as a mean for delivering to the damaged neural tissue of neuro-trophic factors supporting neuron survival, axon growth and establishment of new inter-cellular contacts (neuron-neuron, neuron-glia) (Liew et al., 2007; Lepore and

^a Department of Histology, Cytology and Embryology, Kazan State Medical University, ul. Butlerova 49, R-420012 Kazan, Russia

b Department of Genetics, Faculty of Biology and Soil Sciences, Kazan State University, ul. Kremlevskaya 18, R-420008 Kazan, Russia

^c Department of Genetics and Bioengineering, Yeditepe University, 34755 Kayisdagi, Istanbul, Turkey

^d Stem Cell Bank, Kazan State Medical University, ul. Pionerskaya 14, R-420012 Kazan, Russia

^e Institute of Gene Biology, Russian Academy of Sciences, ul. Vavilova 34/5, R-119334 Moscow, Russia

f Department of Radiology, Hetényi Géza Regional Teaching Hospital, H-5001 Szolnok, Tószegi u. 21, Hungary

g Asklepios-Med Bt. (private practice and research center), H-6722 Szeged, Kossuth Lajos sgt. 23, Hungary

^{*} Corresponding author. Tel.: +36 30 255 6225. E-mail address: palotas@asklepios-med.eu (A. Palotás).